Aileron Therapeutics, Inc(NASDAQ:ALRN) 
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the trea...
Website: http://www.aileronrx.com
Founded: 2001
Full Time Employees: 13
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2024-07-15
P
O 3.15
H 3.15
L 2.77
C 2.98
V 95,820
10EMA 2.98
20EMA 2.98
60EMA 2.98
120EMA 2.98
250EMA 2.98